[0001] The present invention relates to tests wnicn employ antibodies to detect the presence
of particular antigenic substances and more particularly to improved suspensions of
antibody molecules bound to solid support particles which agglutinate in the presence
of the particular antigen to which the antibody is reactive.
BACKGROUND OF THE INVENTION
[0002] Antibodies are large proteinaceous molecules that are produced by animals in response
to the presence of a foreign substance for the purpose of neutralizing that substance.
An antibody molecule may be highly specific, recognizing only a certain site of a
particular molecule which is the antigen to that antibody. Because of their high specificities,
antibodies are very useful in ascertaining the presence or absence of various antigenic
substances, and a number of test procedures, such as radioimmunoassays, have been
developed to take advantage of the specificity of the antibodies. Relatively recently,
monoclonal antibodies have been developed, providing a practical method for assuring
that an antibody fraction contains only a single type of antibody molecule. Monoclonal
antibodies may be substituted for conventional antibody fractions in most diagnostic
tests, providing greater accuracy and reliability than tests which utilize conventional
antibody fractions.
[0003] One particular type of test which has been developed that is particularly useful
for detecting the presence of large antigens having multiple antibody- recognition
sites (antigenic determinants), is an agglutination test. Antibody molecules are bound
to minute particles formed of a polymer and the particle-bound antibody is suspended
in a liquid medium. In the presence of the antigen, the particle-bound antibody attaches
to the recognition sites on the antigen. If antibody molecules on more than one particle
attach to the same antigen molecule, the particles become cross-linked, and as multiple
particles cross-link, they agglutinate and precipitate from the solution. Agglutination
and precipitation of the suspended particles is readily observable by the naked eye,
providing a very simple and very certain test that a particular antigen is present.
[0004] One currently used method of attaching antibodies to polymer particles is described
in Molday, R.S., W.J. Dreyer, A. Rembaum, and S.P.S. Yen; "New Immunolatex Spheres:
Visual Makers of Antigens on Lymphocytes for Scanning Electron Microscopy", J. Cell
Biol (1975) 64, pp. 75-88. Carboxylate derivatized latex particles are reacted with
the antibody in the presence of a carbodiimide, coupling amino groups on the antibody
to the carboxyl groups on the peptide. This procedure is useful for binding relatively
small antibody or immunoglobulin molecules, such as IgG, but does not work in acceptable
fashion for binding larger antibody molecules such as IgM. Furthermore, this method
provides no method for controlling the amount of antibody that binds to the particle.
If excessive amounts of antibody bind to the particles, the particles may tend to
agglutinate prematurely, i.e., before indroduction of the antigen.
[0005] Another method of binding antibodies to latex particles is through adsorption of
antibodies to the surface of latex particles, as is described in Carel J. Van Oss
and J. M. Singer; "The Binding of Immune Globulins and Other Proteins by Polystyrene
Latex Particles", J. Reticuloendothelial Soc. (1966) 3, pp. 29-40. The success of
this procedure depends to a great extent on the exact lot of the latex, different
lots having vastly different adsorptive properties and stabilities. Because of the
unpredictability of results, this procedure is used largely for larger antibody molecules,
such as IgM.
[0006] It would be desirable to provide latex particles having bound antibody which can
be more reproducibly manufactured, irrespective of the type of antibody and irrespective
of the adsorptive properties of the particular lot of latex particles. It would be
further desirable to control the number of antibody molecules binding to the particles
to assure that premature agglutination will not occur due to the particles having
excessive bound antibody molecules and yet assure that there are sufficient bound
antibody molecules to agglutinate the particles rapidly in the presence of the antigen.
SUMMARY OF THE INVENTION
[0007] The invention provides a diagnostic composition comprising a suspension of carboxylate
derivatized latex particles bound to antibody molecules through avidin-biotin bridges.
The latex particles, having multiple free carboxyl groups on their surfaces, are bound
to avidin using a carbodiimide intermediate. Biotin is covalently bound to the antibody.
A mixture of biotin and biotinylated antibody in a predetermined molar ratio are reacted
with the latex-bound avidin, linking antibody moieties to a selected portion of the
avidin binding sites. The number of antibody molecules attached through avidin-biotin
bridges to the latex is controlled to assure that the particles remain in suspension
until they cross-link and agglutinate in the presence of an antigen to the antibody.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] In accordance with the invention, diagnostic particles are provided in which antibodies
are attached to carboxylate-derivatized latex particles through avidin-biotin bridges.
The diagnostic particles comprise carboxylate derivitized polymeric core particles,
avidin moieties linked through amide bonds to the core particles, biotin moieties
complexed to the avidin moities and antibody (immunoglobulin) molecules linked to
the biotin moieties through amide bonds. The diagnostic particles are suspended in
a liquid medium to form a latex composition that is useful for diagnosing the presence
of an antigen to which the bound antibody is specific. The diagnostic particles suspended
in the liquid medium agglutinate by cross-linking through antigen molecules that have
multiple antigenic determinants recognized by the antibody, and the cross-linked diagnostic
particles precipitate from the liquid medium.
[0009] To form the diagnostic particles, carboxylate derivatized latex core particles are
attached to avidin through an amide bond formed between the surface carboxyl groups
of the polymeric core particle and primary amino groups on the avidin. An antibody
of interest is attached to biotin through an amide bond formed by the carboxyl group
of biotinic acid and an amine group of the antibody. Avidin has a very strong affinity
for biotin, and the antibody-bound biotin moiety readily complexes to an avidin moiety
linked to the core particle. To assure that the diagnostic particles will be stable
as a latex suspension until agglutination testing, the number of antibody moieties
linked to each core particle is controlled. To prevent excessive biotinylated antibody
from complexing to the avidin moities linked to the core particles, a mixture of free
biotinic acid.and biotinylated antibody of a predetermined molar ratio is reacted
with the core particle-bound avidin so that biotinic acid occupies a portion of the
binding sites on the avidin which might otherwise be occupied by the biotinylated
antibody.
[0010] The term "latex" herein is used broadly to include stable dispersions of particles
of polymeric material. Suitable latexes include suspensions of minute polystyrene
and polyacrylamide particles. To provide that a stable suspension of the diagnostic
particle can be formed which will precipitate within a reasonable time upon exposure
to the antigen, the starting polymeric core particles should be between about 0.2
and about 1.0 micron in diameter.
[0011] The polymeric core particles are carboxylate derivatized to provide exposed carboxyl
groups at their surfaces for attachment of avidin. Polyacrylamide particles may be
derivatized by the method of John K. Inman, "Covalent Linkage of Functional Groups,
Ligands, and Proteins to Polyacrylamide Beads", in Methods in Enzymology, Vol XXXIV,
(ed. William B. Jakoby and Meir Wilchek, Academic Press, N.Y., 1974) pp. 30-58. Suitable
carboxylate-derivatized latex particles are commercially available; for example, carboxylate-latex
sold by Polysciences. It is found that particles carboxylated to between 0.1 and about
0.5 milliequivalents per gram are most suitable. This degree of carboxylation provides
more surface carboxyl groups than are eventually used to bind avidin and, subsequently,
biotinylated antibody. However, less successful results are achieved with particles
carboxylated to a lesser degree. Therefore, it is not considered desirable to limit
the amount of antibody bound on each particle through the number of carboxyl moieties
on the polymeric core particles.
[0012] The high affinity of avidin for biotinic acid is well known, and the combination
of avidin and biotin are found to provide a very effective means for linking controlled
amounts of antibody to the latex. Biotin (hexahydro-2-oxo-lH-thieno [3,4] imidazole-4-pentanoic
acid) is a growth factor present in very minute amounts of every living cell and is
found mainly bound to proteins or polypeptides. Avidin is a glycoprotein containing
four essentially identical peptide subunits, each having an attached carbohydrate
moiety. Each subunit of avidin has a single biotin binding site. The combined molecular
weight of the subunits is about 66,000. Avidin is most commonly isolated from raw
egg whites but is probably found in the genital tract of all animals. Avidin is also
produced by certain bacteria, such as Streptomyces avidinii, and avidin used herein
is to be understood to refer to animal avidin as well as bacterial avidin, such as
streptavidin. The high affinity of avidin for biotin has been demonstrated by the
ability of large amounts of avidin to produce biotin deficiency in rats and chicks.
[0013] Because the core particles have a greater number of surface carboxyl groups than
are to be eventually linked to antibody molecules, avidin is reacted with the core
particles in amounts less than the stoichiometric concentration which would link to
all core surface carboxyl groups. It is not preferred, however, to control the number
of biotinylated antibody molecules that are subsequently linked to the cores by limiting
the number of avidin molecules that are bound to the cores to the minimum that would
be required to complex stoichiometrically to the desired number of biotinylated antibody
molecules. It is found that best results are achieved when avidin is reacted with
the latex particles to provide between about 10 and about 10
13 molecules of avidin per cm
2 of estimated core particle surface area, and to this end, between about 1.2x10
-3 and about 1.2x10
-2 gm of avidin are reacted per gm of styrene core particles, and between about 1.2x10
-3 and about 1.2x10
-2 gm of avidin are reacted per gm of polyacrylamide core particles.
[0014] The antibody is selected according to the antigen to be detected. Any of the known
types of immunoglobulins can be linked to latex core particles by the method of the
present invention, including IgG, IgA and IgM. A general requirement is that the antibody
be specific for an antigen having at least two antigenic determinants so that the
antigen can bind to antibodies on different diagnostic particles and thereby cross-link
the particles. Many large antigens of interest, such as the group carbohydrate antigen
of Group A Streptococcus, have multiple, substantially identical, antigenic determinants.
If the particular antigen does not have duplicate antigenic determinants, it may have
spaced-apart distinct antigenic determinants, in which case a mixture of two or more
antibodies, each reactive with one of the determinants, might be linked to the latex
core particles to allow cross-linking between diagnostic particles to take place through
the unique antigenic determinants.
[0015] It is preferred that, if available, monoclonal antibodies be used to detect antigens.
Monoclonal antibodies, consisting of identical antibody molecules, are much more specific
than conventionally obtained antibody fractions and provide for much greater reproducability
between lots of diagnostic particles. "Monoclonal antibodies" is used herein to refer
to antibodies generated by hybridomas, as well as antibodies produced by other cell
immortalization techniques, e.g., by infection with certain viruses. However, the
invention is intended to encompass diagnostic particles incorporating conventional
antibody fractions, particularly to detect antigens for which no monoclonal antibody
is presently available.
[0016] The formation of the amide bond between the carboxyl groups on the latex core particles
and an amine group of the avidin is preferably facilitated through an intermediate
formed by reaction of a carbodiimide, such as l-ethyl-3-(3-dimethylaminopropyl) carbodiimide,
with the carboxyl groups on the latex particles. After the carboxyl groups have been
activated through reaction with the carbodiimide, the avidin is introduced, whereupon
primary amino groups on the avidin replace the carbodiimide linked to the carbonyl.
These reactions are represented in equation 1 below:

carbodiimide
[0017] A preferred method of forming the amide bond between the carboxyl group of biotin
and an amino group of the antibody molecule is by initially forming an ester between
an N-hydroxy imide, such as N-hydroxy-succinimide and biotin and then reacting the
N-hydroxy imide-biotin with the immunoglobulin, whereupon an amino group of the immunoglobulin
replaces the N-hydroxyimide linked to the carbonyl. This reaction is carried out at
slightly alkaline conditions, preferably at a pH of between about 7.5 and about 9.0.
These reactions are represented in equation 2 below:

[0018] Because avidin is reacted in less than stoichiometric amounts, unbound surface carboxyl
groups remain on the latex core particles. These unbound carboxyl groups are preferably
neutralized, e.g., with an amine, such as ethanol amine.
[0019] It has been found that diagnostic particles have greater stability if, subsequent
to neutralization, non-immunogenic proteinaceous material, such as bovine serum albumin
(BSA), is adsorbed onto the surfaces of the avidin-bound latex core particle.
[0020] Control of the amount of antibody on the surface of the diagnostic particle, which
is accomplished by mixing free biotinic acid with biotinylated antibody so that they
compete for the excess avidin binding sites, is considered an important aspect of
the invention. Too few antibody molecules may not afford agglutination at a suitable
rate, whereas too many antibody molecules may result in premature precipitation. Generally,
it is preferred that between 2
x10
11 and about 2x10
12 antibody molecules be bound per cm of estimated surface area of the latex core particles,
although this may vary somewhat depending upon whether the antibody is small, e.g.,
IgG, or large, e.g., IgM. The molar ratio of biotinic acid to biotinylated antibody
ratio is dependent on the number of avidin binding sites. It must also be taken into
account that free biotinic acid reacts somewhat more rapidly with the avidin than
does the antibody-bound avidin. Providing a desired amount of antibody on the diagnotic
particles generally requires that a mixture of biotinic acid and biotinylated antibody
in a molar ratio of between about 1:1 and about 10:1 be reacted with particles having
avidin, in the above-mentioned preferred amounts, bound to the core particles. The
reaction between a mixture of biotinylated antibody and biotinic acid with core particle-linked
avidin is represented in equation 3 below: In

[0021] The liquid medium in which the diagnostic particles are suspended is generally aqueous
as is consistent with the natural environment of antibody molecules. A slightly basic
pH, e.g., between about 7.5 and about 8.5, contributes to stability of the diagnostic
particles. Antimicrobial agents, such as NaN
3 may also be added to the medium. Generally latex suspensions for use in agglutination
tests contain between about 5 and about 10 gm. of particles per liter of suspension.
[0022] The invention will now be described in greater detail by way of example.
EXAMPLE
[0023] 4.0 ml of carboxylate-latex at 2.5 weight percent solids, obtained from Polysciences
Inc. Warrington, Pa., is washed three times with distilled water, and after the final
wash, the particles are resuspended in 4.0 ml of distilled water. 1.0 ml of 0.05 M
KH
2P0
4, pH 4.5 is added. The suspension is placed on a magnetic stirrer and maintained at
22°C, and 5 ml. of a solution of 2 weight percent l-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (obtained from Sigma Chem. Co., St. Louis, Mo.) is added and allowed
to react with the latex for 3.5 hours. The carbodiimide-activated carboxylate-latex
is then washed once in saline and resuspended in 5 ml. of saline.
[0024] 1.2 mg of avidin (all procedures are performed in duplicate, once using egg white
avidin and once using streptavidin) is dissolved in 5 ml of 0.2 M borate, pH 8.5,
and the 5 ml. latex suspension is added. The carbodiimide-activated carboxylate-latex
and avidin are allowed to react for 20 hrs. at 22°C. To neutralize surface carboxyl
groups not bound to avidin, 5 mM ethanolamine is added, and then BSA is added to a
concentration of 2 weight percent. The avidin-latex is washed and taken up in 0.1
M glycine-saline, pH 8.2 containing 0.2% NaN
3, 0.2% BSA and 0.05% Tween-20 and stored at 4°C.
[0025] Antibodies are bound to biotin as follows:
A) 1 mg of polyvalent rabbit IgG (anti-group A streptococcal antigen) in 1.0 ml. of
0.2 M NAHCO3 is reacted with 50 ul of a solution of d-biotin-N-hydroxysuccinimide ester in DMSO
(1.0 mg/ml). The reaction is allowed to proceed for 4 hours at 22°C, and the reaction
mixture is then dialized at 4°C for 18 hours against a 500 fold excess of 0.91 M tris-saline
buffer, pH 8.0 containing 0.2% NaN3.
B) 1.0 mg of mouse monoclonal IgG3 (anti-group A streptococcal antigen) in 1.0 ml of 0.2 M NaHCO3 is reacted with 8 ul of a solution of d-biotin-N-hydroxysuccinimide ester in DMSO
(1.0 mg/ml). The reaction is allowed to proceed for 4 hours at 22°C, and the reaction
mixture is then dialyzed at 4°C for 18 hours against a 500 fold excess of 0.01 M tris-saline
buffer, pH 8.0 containing 0.2% NaN3.
C) 1.0 mg of mouse monoclonal IgM (anti-N meningitis B capsular polysaccharide) in
1.0 ml of 0.2 M NaHCO3 is reacted with 8 to 10 ul of a solution of d-biotin-N-hydroxysuccinimide ester in
DMSO (1.0 mg/ml) for 4 hours at 22°C, and the reaction mixture is then dialyzed against
a 500 fold excess of 0.01 M tris-saline buffer, pH 8.0 containing 0.2% NaN3.
[0026] Each of the biotinylated antibodies, formed above, is attached to the avidin-latex
particles. 1.0 ml. of avidin latex is pelleted and the supernatant removed. The pellet
is taken up in 1.0 ml of biotinylated antibody containing 5 µl of 10 M biotinic acid,
and the mixture is stirred for 1 hour at 22°C to react the biotin and biotinylated
antibody. After 1 hour, a second 5 µl aliquot of 10" M biotinic acid is added to block
potentially unoccupied biotin binding sites on the avidin moieties.
[0027] The diagnostic particles are centrifuged, washed and suspended at 0.6% solids in
0.1 M glycine-saline buffer, pH 8.2 containing 0.2% NaN
3, 0.2% BSA and 0.05% Tween-20.
[0028] To 15 ml of the diagnostic particle suspension formed from the polyvalent rabbit
IgG, 50 ml containing 0.1 µg of Group A Streptoccous antigen are added. Agglutination
of the suspension is noted after 4 minutes.
[0029] To 15 ml of the diagnostic particle suspension formed from the mouse monoclonal IgG
3 antibody, 50 ml containing 0.1 pg of Group A Streptococcus antigen are added. Agglutination
of the suspension is noted after 10 minutes.
[0030] To 15 ml of the diagnostic particle suspension formed from the mouse monoclonal IgM
antibody, 50 ml containing 0.1 µg of N mening B polysaccharide antigen are added.
Agglutination of the suspension is noted after 10 minutes.
[0031] Suspensions of diagnostic particles prepared according to the present invention are
stable if stored under refrigeration for periods of several months. The diagnostic
particles are extremely sensitive, and using microtechniques, the suspensions can
be used to detect as little as nanogram quantities of antigen.
[0032] Several advantages of the present invention can now be more fully appreciated. The
invention provides for attachment of all types of immunoglobulins, including IgM.
The amount of antibody attached to the latex is not dependent upon the adsorption
characteristics of a particular lot of latex. Similarly, although the degree of carboxylation
is preferably within a certain range, the amount of antibody attached is determined
independently of the precise degree of carboxylation of the core particles, i.e.,
by the less than stoichiometric amount of avidin bound to the carboxyl groups and
then by the selected molar ratios of biotinic acid and biotinylated antibody. Thus
reproducability of manufacture is significantly enhanced relative to prior latex particle
to antibody linking procedures, particularly with respect to IgM which previously
had to be bound to the latex by the highly variable adsorption technique.
[0033] While the invention has been described in terms of certain preferred embodiments,
modifications obvious to one with ordinary skill in the art may be made without departing
from the scope of the present invention. For example, while it is not preferred, the
amount of antibody bound to the particles could be made through control of the number
of avidin molecules bound to the latex core particles followed by saturation of the
biotin binding sites with biotinylated antibody molecules. While the diagnostic particle
suspensions generally require that the antigen be large, having at least two antigenic
determinant sites, it is also contemplated that a small antigenically active molecule
or hapten could agglutinate the particles if the particles were suspended in a liquid
medium that contained a chemical which would link two or more of the hapten molecules.
[0034] Various features of the present invention are set forth in the following claims:
1. A diagnostic particle comprising
a carboxylate derivatized polymeric core between about 0.2 and about 1.0 micron in
diameter,
a plurality of avidin moieties linked through amide bonds to said core,
a plurality of biotin moieties complexed to said avidin moities, and
a plurality of antibody molecules linked through amide bonds to a significant portion
of said biotin moieties.
2. A diagnostic composition comprising, a plurality of particles, each comprising
a carboxylate derivatized poymeric core between about 0.2 and about 1.0 micron in
diameter, a plurality of avidin moieties linked through amide bonds to said core,
a plurality of biotin moieties complexed to said avidin moieties and a plurality of
antibody molecules linked through amide bonds to a significant portion of said biotin
moieties, and an aqueous medium in which said particles are suspended.
3. A composition acording to claim 2 wherein the particle cores are formed of polyacrylamide
or polystyrene.
4. A composition according to claim 2 or 3 wherein the diagnostic particles have neutralizing
moieties attached to core surface carboxyl groups that are not linked by amide bonds
to avidin.
5. A composition according to any of claims 2 to 4 wherein the diagnostic particles
also include non-immunogenic proteinaceous material adsorbed on surfaces of the cores.
6. A composition according to any of claims 2 to 5 wherein the antibody molecules
are monoclonal antibody molecules.
7. A composition according to any of claims 2 to 6 wherein the cores are carboxylated
to between about 0.1 to about 0.5 milliequivalents per gram of core particles.
8. A method of preparing diagnostic particles comprising
providing carboxylate derivatized polymeric core particles between about 0.2 and about
1.0 micron in diameter,
linking avidin molecules to said core particles through amide bonds,
binding biotin molecules to antibody molecules through amide bonds, and
complexing said cores particle-linked avidin with said antibody molecule-bound biotin.
9. A method according to claim 8, wherin the core particles are carboxylated to between
about 0.1 and about 0.5 milliequivalents per gram of polymer.
10. A method according to claim 8 or 9 wherein the polymer is polystyrene or polyacrylamide.
11. A method according to claim 10 wherein between about 1.2x10-3 and about 1.2x10-2 gm of avidin are linked per gram of core particles.
12. A method according to any of claims 8 to 11 wherein the avidin is egg white avidin
or streptavidin.
13. A method according to nay of claims 8 to 12 including neutralizing surface carboxyl
groups of the core particles not bound to avidin.
14. A method according to claim 13 including adsorbing a non-immunogenic proteinaceous
material onto the surface of the core particles subsequent to avidin linking and carboxyl
group neutralization.
15. A method according to any of claims 8 to 14 which includes controlling the amount
of immunoglobulin molecules by complexing the core particle-linked avidin with a mixture
of free biotinic acid and the antibody-bound biotin.
16. A method according to any of claims 8 to 15 wherein linking the avidin to the
core particles comprises reacting the core paticles with a carbodiimide to form an
intermediate and reacting the intermediate with avidin.
17. A method according to claim 16 wherein linking the biotin to the antibody comprises
reacting the antibody with an N-hydroxy imide to form an ester intermediate.